乌司他丁联合奥曲肽对急性重症胰腺炎的治疗效果  

Therapeutic Effect of Ulinastatin Combined with Octreotide on Severe Acute Pancreatitis

作　　者：唐岩 吉春阳 TANG Yan;JI Chunyang(Hepatobiliary and Pancreatic Medicine of 2nd Gastroenterology Department,Zhumadian Central Hospital,Zhumadian 463000,China)

机构地区：[1]驻马店市中心医院消化二肝胆胰内科,河南驻马店463000

出　　处：《临床医学工程》2024年第12期1499-1500,共2页Clinical Medicine & Engineering

摘　　要：目的探讨乌司他丁联合奥曲肽治疗急性重症胰腺炎(SAP)的临床效果。方法60例SAP患者随机分为两组。在常规治疗基础上,参照组给予奥曲肽治疗,联合组给予乌司他丁联合奥曲肽治疗。比较两组的临床疗效、炎性因子水平、不良反应。结果联合组的治疗总有效率为93.33%,明显高于参照组的73.33%(P<0.05)。治疗后,联合组的血清hs-CRP、IL-6、TNF-α水平均明显低于参照组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论乌司他丁联合奥曲肽治疗SAP可明显减轻患者的机体炎性反应,疗效确切,安全性高。Objective To explore the clinical effect of ulinastatin combined with octreotide in the treatment of severe acute pancreatitis(SAP).Methods 60 patients with SAP were randomly divided into two groups.On the basis of routine treatment,the reference group was treated with octreotide,and the combined group was treated with ulinastatin combined with octreotide.The clinical efficacy,inflammatory factor levels and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the combined group was 93.33%,significantly higher than 73.33%in the reference group(P<0.05).After treatment,the levels of serum hs-CRP,IL-6 and TNF-αin the combined group were significantly lower than those in the reference group(P<0.05).No significant difference was found in the total incidence of adverse reactions between the two groups(P>0.05).Conclusions Ulinastatin combined with octreotide in the treatment of SAP can obviously relieve the body inflammatory response of patients,with exact therapeutic effect and high safety.

关 键 词：急性重症胰腺炎 乌司他丁 奥曲肽 临床疗效 炎性因子 不良反应 

分 类 号：R657.51[医药卫生—外科学]